127 completed. 127 Phase 2, 13 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 127 | Completed 127 |
| Phase 1 | 13 | Completed 13 |
| Phase 3 | 6 | Completed 6 |
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 33 | 2025-10-06 | 2026-01-08 |
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 497 | 2025-07-31 | 2026-09-11 |
| Sedation vs No Sedation in Mechanically Ventilated COPD Patients Midalozam - Chronic Obstructive Pulmonary Disease, Respiratory Failure | Phase 2 | Completed | Al-Azhar University | 100 | 2025-04-14 | 2026-06-02 |
| A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg) - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 46 | 2024-08-16 | 2026-02-09 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 75 | 2023-08-23 | 2025-04-17 |
| Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD Bevespi, Bretzri - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | University of Miami | 25 | 2023-04-11 | 2026-09-08 |
| Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy REGEND001 cell therapy, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Regend Therapeutics | 58 | 2022-12-06 | 2026-09-28 |
| Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD EP395, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | EpiEndo Pharmaceuticals | 61 | 2022-11-22 | 2026-07-01 |
| Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD Itepekimab SAR440340 - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Sanofi | 49 | 2022-05-19 | 2026-08-31 |
| Metformin to Reduce Airway Glucose in COPD Patients Metformin, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Imperial College London | 14 | 2022-05-17 | 2025-02-18 |
| Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes E-Cigarette, Financial Incentives - Chronic Obstructive Pulmonary Disease, Chronic Bronchitis | Phase 2 | Completed | University of Vermont | 21 | 2022-04-28 | 2024-02-08 |
| A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Astegolimab, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Genentech, Inc. | 1334 | 2021-10-05 | 2026-10-16 |
| Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) SelK2 (Part 1), Placebo (Part 1), SelK2 (Part 2) - Asthma, Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Tetherex Pharmaceuticals Corporation | 61 | 2020-08-18 | 2022-02-02 |
| A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. AZD8871, Anoro® Ellipta® - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 73 | 2018-10-10 | 2020-12-17 |
| Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies Belimumab, Placebo - Chronic Obstructive Pulmonary Disease, Emphysema | Phase 2 | Completed | University of Alabama at Birmingham | 17 | 2018-08-09 | 2023-07-18 |
| Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Sanofi | 343 | 2018-07-16 | 2022-11-22 |
| Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) CHF 5993 DPI, CHF5993 pMDI, CHF 1535 pMDI - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 366 | 2018-06-15 | 2021-04-12 |
| Autologous Bronchial Basal Cell Transplantation for Treatment of COPD Bronchial basal cells - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Regend Therapeutics | 24 | 2018-06-12 | 2023-03-24 |
| Short Compared With Standard Duration of Antibiotic Treatment for AECOPD Levofloxacin 500mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | University of Monastir | 310 | 2018-01-01 | 2021-07-16 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 CHF6366, Placebo CHF6366, umeclidinium bromide and vilanterol trifenatate - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 118 | 2017-12-28 | 2020-05-07 |
Showing 20 of 127. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (127) · Emphysema (14) · Bronchitis, Chronic (9) · Lung Diseases (6) · Bronchiolitis Obliterans Syndrome (4) · Dyspnea (4) · Hypertension, Pulmonary (4) · Asthma (3) · Lung Diseases, Obstructive (3) · Respiration Disorders (3) · Disease (2) · Motor Activity (2) · Pulmonary Emphysema (2) · Respiratory Insufficiency (2) · Anxiety Disorders (1)
Chronic Disease (127) · Disease Attributes (127) · Pathologic Processes (127) · Pathological Conditions, Signs and Symptoms (127) · Respiratory Tract Diseases (127) · Lung Diseases, Obstructive (124) · Lung Diseases (121) · Bronchial Diseases (16) · Bronchitis (12) · Infections (11) · Respiratory Tract Infections (11) · Immune System Diseases (9) · Respiration Disorders (9) · Cardiovascular Diseases (7) · Signs and Symptoms (7)
Formoterol Fumarate (13) · Glycopyrrolate (8) · Tiotropium Bromide (8) · Salmeterol Xinafoate (4) · Budesonide (3) · Fluticasone (3) · Ipratropium (3) · ensifentrine (3) · indacaterol (3) · 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)-piperidine (2) · Aspirin (2) · Inhalation (2) · aclidinium bromide (2) · carmoterol (2) · itepekimab (2)
AstraZeneca (12) · Pearl Therapeutics, Inc. (11) · Chiesi Farmaceutici S.p.A. (9) · Novartis (6) · Dey (4) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (4) · Novartis Pharmaceuticals (3) · Sunovion Respiratory Development Inc. (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Regend Therapeutics (2) · Sanofi (2) · US Department of Veterans Affairs (2) · University of Alabama at Birmingham (2) · University of Illinois at Chicago (2) · Adams Respiratory Therapeutics (1)
United States (61) · United Kingdom (26) · Germany (17) · Poland (10) · Netherlands (9) · Australia (8) · Bulgaria (8) · Canada (8) · Belgium (7) · China (6) · Czechia (6) · Hungary (6) · Russia (6) · France (5) · Japan (5)
Colin Reisner, M.D. (6) · Ahmet Tutuncu, MD, PhD (2) · Andrew Lockton, MD (2) · Colin Reisner, MD (2) · Dave Singh (2) · Esther Garcia, MD (2) · Margaret K Covey, PhD, RN (2) · Adam Wanner, MD (1) · Adrian R Martineau, MRCP (1) · Adrian S. Dobs, MD, MHS (1) · Ahmet Tutuncu, M.D., Ph.D. (1)
PMID 24432712, PMID 25287629, PMID 15319045, PMID 16796497, PMID 17296644, PMID 18655841, PMID 18972276, PMID 19017883, PMID 19179484, PMID 19436683, PMID 20541381, PMID 21184620, PMID 21514398, PMID 21524765, PMID 21689019, PMID 22235841, PMID 22280813, PMID 22458939, PMID 23098686, PMID 23217058, PMID 23257347, PMID 23539534, PMID 24484754, PMID 24717626, PMID 24958605, PMID 25027304, PMID 25038985, PMID 25060541, PMID 25243340, PMID 25336939, PMID 25383540, PMID 25476069, PMID 26050967, PMID 26318254, PMID 27586537, PMID 28011397, PMID 28061907, PMID 28331925, PMID 28528348, PMID 28793896, PMID 29496167, PMID 29506504, PMID 29567116, PMID 29695902, PMID 29950826, PMID 30116551, PMID 30166326, PMID 31682162, PMID 32513646, PMID 32962709
2015 (4), 2009 (3), 2017 (2), 2008 (1), 2018 (1), P50AT000437 (1), R01HL033269 (1), R34HL127166 (1), R44AG029087 (1), R44HL073591 (1), U54DA036114 (1)